Report error Found 422 Enz. Inhib. hit(s) with all data for entry = 11742
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.100nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: <0.200nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.300nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.300nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.300nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.400nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.400nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.400nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.400nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.400nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.600nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.600nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.600nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.600nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.600nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.800nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.800nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.800nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.800nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.800nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.800nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics
US Patent
Biosplice Therapeutics
US Patent
Affinity DataEC50: 0.900nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair

















































